Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAK | O14976 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 4/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | QPCT | Q16769 | 3/20 | 0.39 |
| ▸ | PRKCA | P17252 | 2/20 | 0.39 |
| ▸ | PRKCI | P41743 | 2/20 | 0.39 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.39 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3513472 | 0.82 | MAPT (0.67) | MAPTSMN1; SMN2LMNAPOLBGAK | |
| SCHEMBL182931 | 0.67 | PIK3CD (0.59) | KIT | |
| SCHEMBL15765933 | 0.65 | KDM4E (0.54) | MAPTGAAKDM4E | |
| SCHEMBL1424073 | 0.65 | MAPT (0.74) | MAPTSMN1; SMN2LMNAPOLBGAK | |
| SCHEMBL4727573 | 0.65 | FYN (0.60) | MAPTSMN1; SMN2LMNAPOLBGAK | |
| SCHEMBL1424242 | 0.65 | PLAT (0.57) | MAPTSMN1; SMN2LMNAPOLBGAK | |
| SCHEMBL183417 | 0.64 | PIK3CD (0.59) | RETKIT | |
| SCHEMBL6649844 | 0.64 | L3MBTL1 (0.67) | MAPTSMN1; SMN2LMNAPOLBNPC1 | |
| SCHEMBL4558600 | 0.64 | FYN (0.74) | MAPTSMN1; SMN2LMNAPOLBGAK | |
| SCHEMBL4326781 | 0.64 | FYN (0.66) | MAPTSMN1; SMN2LMNAPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | CAPRARO HANS-GEORG | 2010-12-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | PI4KA, PIP5K1B, PIP4K2A | MAPT 4070/4885SMN1; SMN2 4827/4885LMNA 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.